Stupidity is contagious. It gets us all from time to time. Even respectable companies can catch it. As I do every week, let's take a look at five dumb financial events this week that may make your head spin.
1. Frank LINN
LINN Energy (NASDAQ: LINE ) took a hit after revealing that the SEC is launching an inquiry into the company's hedging strategies, accounting metrics, and the proposed purchase of Berry Petroleum.
LINN's been a serial acquirer. It's been snapping up smaller oil and natural gas providers in this highly fragmented sector. LINN racked up $2.9 billion in purchases last year alone and the Berry deal would put it well above that in 2013.
Accounting can get tricky as companies go on buying sprees, but investors tend to steer clear once regulators start launching investigations.
The silver lining for daring income chasers is that LINN's yield just got ridiculously juicy. It declared a monthly cash distribution this week that translates into an annualized yield of 12.7% on the units based on Wednesday's close.
Top Supermarket Stocks To Invest In Right Now: Galectin Therapeutics Inc (GALT)
Galectin Therapeutics Inc., formerly Pro-Pharmaceuticals, Inc., incorporated on January 26, 2001, is a development-stage company. The Company is engaged in drug development to create therapies for cancer and fibrotic disease. As of December 31, 2011, the Company has two compounds in development, one is to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from different natural starting materials, both possessing the property, which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, the Company's product candidate for cancer therapy, is a linear polysaccharide polymer consisted of mannose and galactose that has a defined chemical structure and is derived from a plant source. GR-MD-02, the Company's product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source.
GM-CT-01 has in development for the therapy of colorectal cancer and is in a Phase I/II clinical trial as a combination therapy with a tumor vaccine in patients with advanced melanoma. Based on the completed Phase I and partially completed Phase II clinical trials, the Company is exploring two additional potential indicia for the use of GM-CT-01 in combination with cancer chemotherapy. There are two additional pathways for the development of GM-CT-01 for use in treatment of cancer. GM-CT-01 was found to be generally safe when studied in a Phase I clinical trial in end-stage cancer patients with multiple tumor types alone and in combination with 5-Fluorouracil (5-FU), which is an Food and Drug Administration (FDA)-approved chemotherapy used for treatment of various types of cancer.
Advisors' Opinion:- [By Roberto Pedone]
Galectin Therapeutics (GALT) offers drug research and development to create new therapies for fibrotic disease and cancer. This stock closed up 9.6% to $12.06 in Monday's trading session.
Monday's Volume: 674,000
Three-Month Average Volume: 222,171
Volume % Change: 149%Shares of GALT jumped higher on Monday after Ascendiant initiated coverage on the stock with a buy recommendation.
From a technical perspective, GALT spiked sharply higher here with strong upside volume. This stock has been uptrending for the last three months, with shares ripping higher from its low of $3.95 to its recent high of $13.21. During that move, shares of GALT have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GALT within range of triggering a near-term breakout trade. That trade will hit if GALT manages to take out Monday's high of $12.44 and then once it clears its 52-week high at $13.21 with high volume.
Traders should now look for long-biased trades in GALT as long as it's trending above some near-term support levels at $11 or at $10 and then once it sustains a move or close above those breakout levels with volume that hits near or above 222,171 shares. If that breakout hits soon, then GALT will set up to enter new 52-week-high territory above $13.21, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $16.
Top Heal Care Companies To Invest In 2014: Peregrine Pharmaceuticals Inc.(PPHM)
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment of cancer and viral infections. Its products under development include bavituximab, a phosphatidylserine-targeting antibody, which is in Phase II trials for the treatment of front-line and second-line non-small cell lung cancer (NSCLC), and pancreatic cancer; and Cotara, a DNA/histone-targeting antibody that is in Phase II trial for the treatment of recurrent glioblastoma multiforme. The company is also developing bavituximab in combination with ribavirin, which is in Phase II clinical trial for the treatment of patients with genotype-1 hepatitis C virus infection. In addition, it has investigator-sponsored trial programs that evaluate bavituximab for the treatment of patients with liver cancer, second-line castration resistant prostate cancer, HER-2 negative metastatic breast cancer, and locally advanced or metasta tic NSCLC. Further, the company, through its wholly-owned subsidiary, Avid Bioservices, Inc., provides integrated current Good Manufacturing Practices (cGMP) commercial and clinical manufacturing services in the United States, including contract manufacturing of antibodies, recombinant proteins, and enzymes; cell culture development; process development; and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has licensing agreements with the University of Texas Southwestern Medical Center; Merck KGaA; SuperGen, Inc.; and Affitech A/S. Peregrine Pharmaceuticals, Inc. intends to sell its products in the United States and internationally in collaboration with marketing partners or through a direct sales force. The company was founded in 1981 and is based in Tustin, California.
Advisors' Opinion:- [By Rick Munarriz]
I went out on a limb last week, and now it's time to see how that decision played out.
I predicted that Noodles & Co. (NASDAQ: NDLS ) would close lower on the week. After seeing the fresh IPO more than double and command a $1.3 billion market cap far sooner than its fundamentals should allow, I figured it would be in for reality check. A negative Barron's piece kicked off the week in the seemingly appropriate bearish tone, but the shares did start to claw their way back later in the week. It wasn't enough. The shares fell 3% on the week. I was right. I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. (DJINDICES: ^DJI ) . This has been a tricky call lately, so how did it play out this time? Well, the market closed nicely higher this week. The Nasdaq moved 3.5% higher, and the Dow managed to close just 2.2% higher. I was right. My final call was for Peregrine Pharmaceuticals (NASDAQ: PPHM ) to beat Wall Street's income estimates in its latest quarter. The upstart biotech tackling cancer through monoclonal antibodies has been posting blowout quarterly results over the past year, and I was banking on seeing the trend continue. Analysts were looking for a loss of $0.06 a share during the quarter, and it came through with exactly that. It wasn't a beat, though, so I was wrong.Two out of three? I can do better than that.
- [By Sean Williams]
Also gaining double digits on the week was the highly embattled Peregrine Pharmaceuticals (NASDAQ: PPHM ) which rallied after the FDA approved its late-stage trial design for its second-line non-small-cell lung cancer immunotherapy, Bavituximab. While trial design approvals are rarely big news, it is in this case because mid-stage results for Bavituximab have been all over the place. At first Bavituximab demonstrated a better than doubling in progression-free survival followed weeks later by management's insistence that investors were not to trust the data. A few months later, following a review, we were told to trust the data again. This filing helps relieve some of the confusion surrounding Peregrine's mid-stage results, and hopefully its phase 3 study will be black-and-white obvious as to whether Bavituximab provides a statistically significant benefit.
- [By Tom Bemis]
Few major companies are reporting after Monday�� bell. Results are expected from Destiny Media Technologies (DSNY) �, Stanley Furniture Co. (STLY) � and Peregrine Pharmaceuticals. (PPHM) �.
Top Heal Care Companies To Invest In 2014: RELM Wireless Corp (RWC)
RELM Wireless Corporation (RELM) provides two-way radio communications equipment. RELM designs, manufactures and markets wireless communications products consisting of two-way land mobile radios, repeaters, base stations, and related components and subsystems. Two-way land mobile radios can be units that are hand-held (portable) or installed in vehicles (mobile). The Company's P-25 digital products and the Company's analog products function in the VHF (136 megahertz - 174 megahertz), UHF (380 megahertz - 470 megahertz, 450 megahertz - 520 megahertz) and 700-800 megahertz bands. The Company offers products under two brand names: BK Radio and RELM. BK Radio-branded products serve the government and public safety market and RELM-branded products serve the business and industrial market.
BK Radio-branded products consist of land-mobile radio equipment for professional radio users primarily in government and public safety applications. RELM's P-25 digital products are marketed under the BK Radio brand. RELM-branded products provide two-way communications for commercial and industrial concerns, such as hotels, construction firms, schools, and transportation services. The Company provides products to a range of customers, including emergency, public safety, homeland security and military customers of federal and state government agencies, as well as various commercial enterprises. The Company's two-way radio products are used in harsh and hazardous conditions.
The Company competes with Motorola Solutions, Inc.
Advisors' Opinion:- [By Roberto Pedone]
Relm Wireless (RWC) is engaged in the designing, manufacturing and marketing wireless communications products consisting of two-way land mobile radios, repeaters, base stations and related components and subsystems. This stock closed up 2.8% to $3.58 in Tuesday's trading session.
Tuesday's Range: $3.40-$3.58
52-Week Range: $1.42-$3.74
Tuesday's Volume: 106,000
Three-Month Average Volume: 74,659From a technical perspective, RWC trended higher here right above some near-term support levels at $3.20 to $3.10 with above-average volume. This stock has been uptrending for the last two months, with shares moving higher from its low of $2.62 to its intraday high of $3.58. During that move, shares of RWC have been making mostly higher lows and higher highs, which is bullish technical price action. That move is quickly pushing shares of RWC within range of triggering a major breakout trade. That trade will hit if RWC manages to take out its 52-week high at $3.74 with high volume.
Traders should now look for long-biased trades in RWC as long as it's trending above some near-term support levels at $3.20 or its 50-day at $3.10 and then once it sustains a move or close above $3.74 with volume that hits near or above 74,659 shares. If that breakout hits soon, then RWC will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $4.50 to $5.
Top Heal Care Companies To Invest In 2014: InSite Vision Inc (INSV)
InSite Vision Incorporated (InSite), incorporated in 1986, is an ophthalmic product development company advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company's current portfolio of products is based on the Company's DuraSite sustained drug delivery technology. Its DuraSite sustained drug delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a wide variety of drug candidates. The Company is focused its research and development and commercial support efforts on the topical products formulated with its DuraSite drug delivery technology. It may also utilize its DuraSite technology platform for the formulation of new ocular product candidates using either non drugs or compounds developed by others for non-ophthalmic indications.
AzaSite (azithromycin ophthalmic solution) 1% is a DuraSite formulation of azithromycin developed as a spectrum ocular antibiotic and approved by the United States Food and Drug Administration (FDA) to treat bacterial conjunctivitis (pink eye). Azithromycin has a spectrum of antibiotic activity and is used to treat respiratory and other infections in its oral and parenteral forms.
Besivance (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a spectrum ocular antibiotic approved by the FDA to treat bacterial conjunctivitis (pink eye). Besivance is the fluoroquinolone specifically developed for ophthalmic use. AzaSite Plus (ISV-502) is a fixed combination of azithromycin and dexamethasone in DuraSite for the treatment of ocular inflammation and infection (blepharitis and/or blepharoconjunctivitis).
DexaSite (ISV-305) is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. DexaSite is included in the Phase 3 clinical trial SPA for ! AzaSite Plus. The Company developed a topical formulation of the corticosteroid dexamethasone to treat eye inflammation caused by infections, injury, surgery or other conditions.
BromSite (ISV-303) is a DuraSite formulation of bromfenac in development for the treatment of post-operative inflammation and eye pain. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease.
The Company competes with Alcon Laboratories, Inc., Allergan, Inc., Bausch & Lomb, Novartis Ophthalmics, Johnson & Johnson, Merck & Co. and Pfizer.
Advisors' Opinion:- [By CRWE]
Today, INSV has shed (-2.74%) down -0.009 at $.320 with 15,483 shares in play thus far (ref. google finance Delayed: 10:59AM EDT June 28, 2013), but don�� let this get you down.
InSite Vision Incorporated previously reported the company has regained North American development rights to azithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra�� from Inspire Pharmaceuticals Inc., a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada. AzaSite Xtra, formulated in InSite�� DuraSite庐 topical drug delivery system, is a product candidate intended for the topical treatment of ocular infections.
- [By CRWE]
Today, INSV surged (+7.53%) up +0.014 at $.200 with 96,500 shares in play thus far (ref. google finance Delayed: 1:12PM EDT August 15, 2013).
InSite Vision Incorporated previously reported financial results for the quarter ended June 30, 2013. Revenues for the second quarter of 2013 were $19.2 million compared to $1.8 million for the same period in 2012. Included in the second quarter of 2013 were revenues of $15 million for the sale of the Besivance庐 royalty rights. Net income for the second quarter of 2013 was $12.1 million, or $0.09 per share, compared to a net loss of $6.8 million, or $0.05 per share, in the second quarter of 2012.
- [By CRWE]
Today, INSV surged (+2.77%) up +0.009 at $.334 with 24,100 shares in play thus far (ref. google finance Delayed: 11:27AM EDT July 8, 2013).
InSite Vision Incorporated previously reported it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on its DuraSite庐 2 next-generation enhanced drug delivery system. DuraSite 2 provides a broad platform for developing topically delivered ocular drugs with enhanced tissue penetration in order to improve efficacy and dosing convenience. The patent is expected to provide protection to 2029 for both the delivery system and the drugs that are formulated with DuraSite 2.
Top Heal Care Companies To Invest In 2014: PowerShares International Dividend Achievers Portfolio (PID)
PowerShares International Dividend Achievers Portfolio (the Fund) seeks to replicate, before fees and expenses, the International Dividend Achievers Index (the Index). The Fund invests in sectors, including financials, utilities, consumer staples, commercial banks, insurance, utilities and information technology. PowerShares Capital Management LLC is the adviser of the Fund.
The Index seeks to identify an international group of American Depository Receipts that have qualified as International Dividend Achievers. The Index is designed to track the performance of dividend paying American Depository Receipts and non-United States common or ordinary stocks trading on the NYSE, NADDAQ or AMEX.
Advisors' Opinion:- [By Carlton Delfeld]
Second, add to the mix, one of my long-time favorite ETFs, the PowerShares International Dividend Achievers (PID).
To get into this exclusive basket, companies have to have a record of increasing dividends for five consecutive years. The United Kingdom and Canada make up 50% of its holdings with the US at only 6%.
- [By Editor , DividendChannel.com]
According to the ETF Finder at ETF Channel, Enbridge stock is an underlying holding representing 1.97% of the Powershares International Dividend Achievers ETF (PID), which holds $20,709,837 worth of ENB shares.
Top Heal Care Companies To Invest In 2014: Vanguard Reit Etf (VNQ)
Vanguard REIT ETF (the Fund), formerly known as Vanguard REIT VIPERs, is an exchange-traded share class of Vanguard REIT Index Fund. The Fund seeks to provide a high level of income and moderate long-term capital appreciation by tracking the performance of an index that measures the performance of publicly traded equity real estate investment trusts (REITs). Vanguard REIT ETF employs a passive management or indexing investment approach designed to track the performance of the MSCI US REIT Index (the Index), an index of United States property trusts that covers about two-thirds of the value of the entire United States REIT market.
Vanguard REIT ETF normally invests approximately 98% of assets in stocks issued by equity REITs. The Fund invests in the stocks that make up the Index, and the remaining assets are allocated to cash investments.
Advisors' Opinion:- [By Dan Caplinger]
3. Real-estate investment trusts
Rate-sensitive REITs took another big hit over the week, with the Vanguard REIT ETF (NYSEMKT: VNQ ) dropping more than 5%. Leveraged mortgage REITs saw even worse losses, with Annaly Capital (NYSE: NLY ) falling more than 7% and American Capital Agency (NASDAQ: AGNC ) seeing 8% declines. - [By John Udovich]
Small cap Biomed Realty Trust Inc (NYSE: BMR) is a real estate investment trust (REIT) offering an alternative way to gain exposure to the biotech or life sciences sector, meaning it might be worth taking a closer look at it along with a few benchmarks like the Vanguard REIT ETF (NYSEARCA: VNQ), iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI). Of course, it should be mentioned that REITs have had a rough ride lately�given all the ��apering��talk, but there is still a place for them in your portfolio with Biomed Realty Trust being one of the more unique offerings.
- [By Howard Gold]
In May, I said real estate investment trusts (REITs) ��ave outperformed the S&P 500 for 11 of the last 16 quarters��and so ��'d be inclined to take at least some profits.��That column ran pretty close to REITs' all-time high and the Vanguard REIT Index ETF (VNQ) has lost 11% of its value.
- [By Dan Caplinger]
Keeping it simple
Some advisors will suggest that you're giving up big potential returns if you don't pick individual stocks. But a portfolio that relies on the broad-based ETFs Vanguard Total Stock Market (NYSEMKT: VTI ) , iShares Core Bond Market (NYSEMKT: AGG ) , Vanguard REIT (NYSEMKT: VNQ ) , or other similar ETFs from other fund companies will get you most of the way to the returns that you need in order to retire comfortably. These three ETFs are particularly useful because they come with low fees, but as long as the ETF you choose doesn't charge too much, there are plenty of strong options to pick from. Insurance coverage can be extremely difficult to understand, and the costs involved can be high. Sticking with basic insurance early on and later adding features as you become more familiar with the risks involved might not always be the least expensive solution to your insurance needs, as in some cases, the earlier you get coverage, the less it costs. Moreover, you won't always qualify to get insurance if some event occurs later in life that boosts your risk to the point at which insurance companies won't offer you coverage at all. But the wait-and-see strategy does have the benefit of preventing you from getting coverage that might well be obsolete or unnecessary by the time you seek to use it.
Even though retirement planning can get complicated in a hurry, the key to remember throughout much of your career is that it's impossible to plan for every contingency you'll face. As a result, the simpler way to handle planning for retirement is to address the threats that you can control while maintaining as much flexibility as possible to handle the threats you can't control -- or might not even be aware of. A few examples include:Admittedly, these simple solutions won't always take care of every contingency, and they can leave you vulnerable to certain risks that require advanced planning techniques. But
Top Heal Care Companies To Invest In 2014: Salix Pharmaceuticals Ltd (SLXP)
Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�� products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.
Xifaxan (rifaximin) tablets
Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers��diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.
It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.
In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla�� application related to amorphous rifaximin and Solmag SpA�� application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.
MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution
MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.
Apriso (mesalamine) extended-release capsules 0.375 gram
Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product�� prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.
Relistor (methylnaltrexone bromide)
Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.
OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets
Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.
Solesta
Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.
Deflux
Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.
Fulyzaq (crofelemer) delayed-release tablets
On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.
Giazo (balsalazide disodium) tablets
February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.
Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets
METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.
Azasan (azathioprine) tablets
Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.
Anusol-HC and Proctocort (hydrocortisone) creams and suppositories
The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.
Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)
Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.
Colazal (balsalazide disodium) capsules
The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.
The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.
Advisors' Opinion:- [By Ben Levisohn]
Salix Pharmaceuticals (SLXP) has jumped 5.9% to $160� on reports it was in talk to sell itself to Actavis (ACT). It was also upgraded to Neutral from Underperform at Credit Suisse.
- [By Paul Ausick]
Stocks on the Move: Twitter Inc. (NYSE: TWTR) is down 7.3% at $41.64 on its second day of trading and word is that some hedge funds and traders are looking to borrow shares. Santarus Inc. (NASDAQ: SNTS) is up 37.6% at $31.95 after agreeing late Thursday night to an acquisition by Salix Pharmaceuticals Inc. (NASDAQ: SLXP) for $2.6 billion in cash.
- [By Anna Prior]
Salix Pharmaceuticals Ltd.(SLXP) agreed to combine with an Ireland-based unit of Cosmo Pharmaceuticals SpA(COPN.EB) in an inversion deal that is expected to come with tax benefits. Salix shares slipped 5.3% to $130.00 premarket.
No comments:
Post a Comment